Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180927

SCHEMBL7180927

SCHEMBL7180927

Cc1cc(C)c(C(=O)C(CP=O)c2ccccc2)c(C)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ GAA P10253 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ PTGFR P43088 3/20 0.33
▸ TAS1R3 Q7RTX0 1/20 0.33
▸ TAS1R1 Q7RTX1 1/20 0.33
▸ KCNQ2 O43526 1/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ EPHX1 P07099 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181039 0.86 LMNA (0.37) LMNAHSD17B10ALDH1A1SMN1; SMN2GAA
SCHEMBL7188486 0.86 SLC6A2 (0.38) LMNAHSD17B10ALDH1A1SMN1; SMN2GAA
SCHEMBL7175023 0.84 LMNA (0.35) LMNAHSD17B10ALDH1A1SMN1; SMN2GAA
SCHEMBL7176015 0.83 LMNA (0.35) LMNAHSD17B10ALDH1A1SMN1; SMN2GAA
SCHEMBL7188465 0.83 LMNA (0.36) LMNAHSD17B10ALDH1A1SMN1; SMN2GAA
SCHEMBL7186879 0.82 L3MBTL1 (0.43) LMNAHSD17B10ALDH1A1SMN1; SMN2GAA
SCHEMBL7183772 0.82 CYP1A2 (0.37) LMNAHSD17B10ALDH1A1SMN1; SMN2CYP2C19
SCHEMBL7177680 0.78 L3MBTL1 (0.36) LMNAHSD17B10ALDH1A1GAAHTT
SCHEMBL7183707 0.77 ATM (0.30) L3MBTL1
SCHEMBL7182855 0.77 KCNQ2 (0.43) LMNAHSD17B10L3MBTL1KCNQ2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885HSD17B10 56/4885ALDH1A1 3416/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885HSD17B10 42/4885ALDH1A1 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.